Inactive Instrument

Company Galapagos NV Euronext Bruxelles

Stocks

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles Other stock markets
-	-

06-10	Lakefront Biotherapeutics Kicks Off Up to EUR50 Million Share Buyback Program	MT
06-09	Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program	MT

Business description: Galapagos NV

Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.

Sales by Activity: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Research and Development (R&D)	485M	505M	240M	276M	1.11B

See all business segments

Geographical breakdown of sales: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Europe	2.11M	3.55M	16K	34.86M	-
United States of America	468M	414M	240M	241M	-

See all geographic segments

Executive Committee: Galapagos NV

Manager	Title	Age	Since
Henry Gosebruch CEO	Chief Executive Officer	53	2025-05-12
Aaron Cox DFI	Director of Finance/CFO	43	2025-07-06
Eric Hedrick CTO	Chief Tech/Sci/R&D Officer	61	2026-06-07
Robert Hughes CTO	Chief Tech/Sci/R&D Officer	-	2023-12-31
Sandra Cauwenberghs IRC	Investor Relations Contact	-	2020-10-31

See GALAPAGOS NV governance

Composition of the Board of Directors: Galapagos NV

Director	Title	Age	Since
Linda Higgins BRD	Director/Board Member	64	2019-10-21
Oleg Nodelman BRD	Director/Board Member	49	2024-10-06
Henry Gosebruch BRD	Director/Board Member	53	2025-05-12
Dawn Svoronos BRD	Director/Board Member	72	2025-07-27
Jane Griffiths BRD	Director/Board Member	71	2025-07-27
Neil G. Johnston BRD	Director/Board Member	-	2025-10-31
Devang Bhuva BRD	Director/Board Member	-	2025-10-31
Paulo Fontoura BRD	Director/Board Member	-	2026-02-08
Gino Santini CHM	Chairman	69	2026-04-27

Composition of the Board of Directors

Shareholders: Galapagos NV

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	477 M
EcoR1 Capital, LLC 10.92 %	7,193,777	10.92 %	205 M
Van Herk Investments BV 7.035 %	4,635,672	7.035 %	132 M
De Grote Voskuil Capital BV 0.3794 %	250,000	0.3794 %	7 M
Saint Olive Gestion SNC 0.0645 %	42,500	0.0645 %	1 M

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	474 M
Tang Capital Management LLC 5.745 %	3,785,991	5.745 %	107 M
Madison Avenue Partners LP 3.741 %	2,465,179	3.741 %	70 M
EcoR1 Capital, LLC 2.53 %	1,667,119	2.53 %	47 M
Prosight Management LP 2.352 %	1,550,000	2.352 %	44 M

List of GALAPAGOS NV shareholders

Company details: Galapagos NV

Galapagos NV

Industriepark Mechelen Noord

2800, Mechelen

+32 1 534 29 00

http://www.galapagos.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.35%	+0.97%	-15.96%	-12.73%	42.96B
REVOLUTION MEDICINES, INC.	+3.17%	+3.24%	+274.75%	+508.69%	31.73B
IQVIA HOLDINGS INC.	-0.09%	-1.57%	+13.47%	-14.79%	30.22B
BEONE MEDICINES AG	+1.70%	-2.13%	-4.40%	+24.00%	28.94B
CELLTRION, INC.	+4.09%	-1.98%	+11.99%	+17.37%	23.87B
MEDPACE HOLDINGS, INC.	-1.33%	+3.26%	+54.29%	+115.14%	13.57B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.06%	+7.59%	12.96B
ASCENDIS PHARMA A/S	+2.44%	+5.13%	-	-	13.39B
IONIS PHARMACEUTICALS, INC.	-0.93%	-1.83%	+105.26%	+75.63%	12.2B
Average	+0.91%	-0.71%	+55.68%	+90.11%	23.31B
Weighted average by Cap.	+1.05%	-1.08%	+54.45%	+95.90%